- Home
- DSGN vs ATNI Comparison
DSGN vs ATNI Comparison
Compare DSGN & ATNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- ATNI
- Stock Information
- Founded
- DSGN 2017
- ATNI 1987
- Country
- DSGN United States
- ATNI United States
- Employees
- DSGN N/A
- ATNI N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- ATNI Telecommunications Equipment
- Sector
- DSGN Health Care
- ATNI Telecommunications
- Exchange
- DSGN Nasdaq
- ATNI Nasdaq
- Market Cap
- DSGN 224.8M
- ATNI 240.0M
- IPO Year
- DSGN 2021
- ATNI 1991
- Fundamental
- Price
- DSGN $3.71
- ATNI $15.26
- Analyst Decision
- DSGN Hold
- ATNI Strong Buy
- Analyst Count
- DSGN 1
- ATNI 1
- Target Price
- DSGN $4.00
- ATNI $30.00
- AVG Volume (30 Days)
- DSGN 93.8K
- ATNI 45.7K
- Earning Date
- DSGN 08-04-2025
- ATNI 07-23-2025
- Dividend Yield
- DSGN N/A
- ATNI 6.29%
- EPS Growth
- DSGN N/A
- ATNI N/A
- EPS
- DSGN N/A
- ATNI N/A
- Revenue
- DSGN N/A
- ATNI $721,575,000.00
- Revenue This Year
- DSGN N/A
- ATNI $2.03
- Revenue Next Year
- DSGN N/A
- ATNI $1.59
- P/E Ratio
- DSGN N/A
- ATNI N/A
- Revenue Growth
- DSGN N/A
- ATNI N/A
- 52 Week Low
- DSGN $2.60
- ATNI $13.76
- 52 Week High
- DSGN $7.77
- ATNI $33.72
- Technical
- Relative Strength Index (RSI)
- DSGN 47.78
- ATNI 45.12
- Support Level
- DSGN $3.66
- ATNI $15.22
- Resistance Level
- DSGN $3.84
- ATNI $16.11
- Average True Range (ATR)
- DSGN 0.25
- ATNI 0.52
- MACD
- DSGN -0.02
- ATNI 0.06
- Stochastic Oscillator
- DSGN 18.06
- ATNI 46.98
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About ATNI ATN International Inc.
ATN International Inc is a telecommunications and utilities company. The company provides digital infrastructure and communications services with a focus on rural and remote markets in the United States, and internationally, including Bermuda and the Caribbean region. Its operating segments comprise U.S. Telecom and International Telecom. The company earns revenue from its International telecommunication segment.